Bioquell PLC Further re Disposal (2698B)
January 08 2018 - 9:39AM
UK Regulatory
TIDMBQE
RNS Number : 2698B
Bioquell PLC
08 January 2018
8 January 2018
Bioquell PLC - Disposal of UK Airflow Business
Bioquell PLC ("Bioquell") (LSE symbol: BQE) - a leading provider
of bio-decontamination products and services for the Life Sciences,
Pharmaceutical and Healthcare markets today announces the
completion of the disposal of its UK AirFlow service and parts
business ("Airflow").
As previously announced on 2 August 2017, Bioquell sold its
Airflow service business to Crowthorne Hi Tec Services Ltd
("CHTS"). The consideration for this part of the business was
GBP169,000 payable in cash on completion and a further GBP70,000
payable on 2 January 2018, which has now been received.
CHTS at that time acquired an option to acquire the related
spare parts and filter manufacturing equipment business on or about
1 January 2018 for a cash consideration of the aggregate of
GBP100,000 and the agreed value for the stock of this business,
which it has chosen to exercise. The aggregate consideration for
the spare parts and filter manufacturing equipment business, paid
on completion, was GBP122,000. The spare parts and filter
manufacturing business had revenue of around GBP0.24m and generated
profits before interest and taxation of approximately GBP0.1m in
the year ended 31 December 2017.
Bioquell is expected to recognise an exceptional gain on the
disposal of Airflow of approximately GBP0.25m in its accounts for
the year ended 31(st) December 2017.
Commenting on the strategic disposal, Ian Johnson, Executive
Chairman of Bioquell PLC, said:
"I am pleased to have been able to conclude these disposals so
we can focus our resources on serving our core bio-decontamination
customers."
Enquiries:
Ian Johnson Executive Chairman Bioquell PLC 01264 835900
Michael Roller Finance Director
***********************************************
Notes to Editors:
Bioquell is a UK-headquartered, international technology company
(www.bioquell.com) which develops, manufactures and sells
specialist biological contamination control products and services
into the Life Sciences, pharmaceutical and healthcare sectors, with
most of its revenues generated from overseas customers.
-- Bioquell's bio-decontamination technology uses hydrogen
peroxide vapour which is highly effective at eradicating
micro-organisms such as bacteria and viruses at room temperature -
and is subsequently broken down at the end of the
bio-decontamination process into water vapour and oxygen (hence an
extremely 'green' technology). Bioquell has a number of patents
associated with this technology.
-- Bioquell has also developed a number of products which
complement its core hydrogen peroxide vapour technology. The
recently introduced Bioquell Sequre, an ergonomic fixed,
wall-mounted bio-decontamination system for small rooms and pass
through chambers; the Bioquell Qube, a novel, modular aseptic
work-station; and the Bioquell POD, a fast-to-deploy single patient
room primarily for infection control in hospitals, are all the
result of a customer focused, solutions based approach to
development that has been employed.
-- Bioquell's products and services are sold by wholly-owned
Bioquell organisations in the UK, USA, France, Germany, Ireland,
Singapore, China and through a network of international
distributors.
Bioquell also develops, manufactures and sells environmental
control equipment into the defence industry, including chemical,
biological, radiological and nuclear filtration systems.
Further information for investors can be found at
www.bioquellplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DISUWOVRWNAARAR
(END) Dow Jones Newswires
January 08, 2018 10:39 ET (15:39 GMT)
Bioquell (LSE:BQE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Bioquell (LSE:BQE)
Historical Stock Chart
From Jan 2024 to Jan 2025